A5004448919- Hemoglobinopathies and Related Disorders
- Iron Metabolism and Disorders
- Acute Myeloid Leukemia Research
- Biosensors and Analytical Detection
- Acute Lymphoblastic Leukemia research
- Blood groups and transfusion
- Epilepsy research and treatment
- Hematopoietic Stem Cell Transplantation
- Hemophilia Treatment and Research
- SARS-CoV-2 detection and testing
Tulane University
2011-2024
The measurement of hemoglobin concentration ([Hb]) is performed routinely as a part complete blood cell count to evaluate the oxygen-carrying capacity blood. Devices currently available physicians and clinical laboratories for measuring [Hb] are accurate, operate on small samples, provide results rapidly, but may be prohibitively expensive resource-limited settings. unavailability accurate inexpensive diagnostic tools often precludes proper diagnosis anemia in low-income developing...
This communication describes a very simple, rapid and inexpensive point-of-care diagnostic test for sickle cell disease (SCD) that can conclusively differentiate between blood samples from normal healthy individuals, trait carriers SCD patients using the characteristic stain patterns produced by each sample on paper.
High-dose busulfan, cyclophosphamide, and antithymocyte globulin (BU-CY-ATG) is the most commonly used conditioning regimen in HLA-matched related hematopoietic cell transplantation for children with sickle disease. Disease-free survival this now approximately 95%; however, it produces significant morbidity. We hypothesized we could create a less toxic by adding fludarabine (FLU) to BU-CY-ATG reduce dosages of busulfan cyclophosphamide. conducted multicenter dose de-escalation trial...
Dear Editor, The primary goal of treatment persons with haemophilia A (PwHA) is prevention or reduction bleeding events; other goals are pain reduction, joint damage and disability to improve quality life (QoL).1 Standard care for PwHA without inhibitors in those severe disease has long been prophylactic intravenous infusions factor VIII (FVIII) replacement. New options have become available recent years, including extended half-life factor- non-factor-based therapies. different treatments a...